About the Collaboration
Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center (BIDMC) are embarking on a long-term collaboration. The collaboration will include all aspects of adult cancer care, building on each organization’s legacy of excellence with compassion, innovative research, and world-class patient care. As part of the collaboration, Dana-Farber and BIDMC plan to build New England’s only freestanding, adult inpatient cancer hospital, where world-class clinicians can deliver transformational medicine in an environment dedicated solely to defying cancer. Dana-Farber will continue to employ medical oncologists and supportive oncology clinicians at its outpatient and inpatient facilities. Harvard Medical Faculty Physicians (HMFP), the physician organization of BIDMC, employs BIDMC physicians, including some of whom will be part of the new collaboration.
New clinical collaborations of this magnitude don't happen often. This is a unique opportunity to shape the future of oncology care. In addition to their appointments and responsibilities at BIDMC and Harvard Medical School, HMFP faculty will work closely with Dana-Farber medical oncologists and will be integral members of the Dana-Farber community when the collaboration begins.
The collaboration includes all aspects of adult cancer care, building on each organization's legacy of excellence with compassion, innovative research, and world-class patient care. The collaboration will offer state-of-the-art, multidisciplinary hematology/oncology care, world-class oncology research, and leadership in the development of therapeutics, screening, and public health interventions in cancer. This exciting collaboration will be the future for all hematology/oncology services at BIDMC, creating a program that will be a recognized global leader in the treatment and understanding of cancer.
Learn more about opportunities at HMFP in the following positions:
